Skip Navigation LinksHome > August 2013 - Volume 19 - Issue 4, Multiple Sclerosis > Multiple Sclerosis Treatment: Risk Mitigation
CONTINUUM: Lifelong Learning in Neurology:
doi: 10.1212/01.CON.0000433280.10523.f0
Practice Issues

Multiple Sclerosis Treatment: Risk Mitigation

Ontaneda, Daniel MD, MS; Fox, Robert J. MD, FAAN

Collapse Box

Abstract

The growing number of disease-modifying medications approved for multiple sclerosis (MS) treatment is a significant step forward and provides new options for our patients. These medications, however, have differing efficacy and risk profiles. Although accurate predictors of efficacy are not available, treatment choices can be guided by patient-specific risk stratification. The use of risk mitigation strategies can help clinicians tailor MS treatment recommendations for individual patients.

Copyright © 2013 by the American Academy of Neurology.

You currently do not have access to this article.

You may need to:

Note: If your society membership provides for full-access to this article, you may need to login on your society’s web site first.

Login